BSE: 539278
Symbiox Investment & Trading C
Operates in the investment and trading space, with a balance sheet of Rs 31.976 crore in total assets as of FY26. The company earns revenue from its investment and trading activities — Rs 1.6029 crore in FY26, producing a net profit of Rs 0.1505 crore. Quarterly income is highly uneven, with Q3 FY26 at Rs 8.60 lakh versus Rs 77.56 lakh in the year-ago quarter, indicating lumpy, transaction-driven realizations rather than a recurring income stream. The cost base is small, with employee costs at 12.8% of revenue and other operating expenses at 12.0%, while materials and capex are negligible. Equity stands at Rs 3,187.63 lakh, almost the entire Rs 3,197.60 lakh asset base. The filings do not detail what specific instruments or assets the company invests in or trades; they confirm only that the entity operates in this space. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Investment and trading activities. Small, listed investment and trading company with episodic, lumpy revenue
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1 | 4 | 4 | 3 | 2 |
| EBITDA (ex other income) | (1) | 0 | 0 | 0 | 0 |
| margin % | (50.4) | 5.0 | 0.5 | 9.3 | 12.9 |
| Owners' profit | 0 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 0.04 | 0.05 | 0.07 | 0.06 | 0.05 |
| ROE % · ROCE % | 0.4 · 0.6 | 0.5 · 0.7 | 0.7 · 0.8 | 0.6 · 0.8 | 0.5 · 0.6 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | (0) | (4) | (0) | 4 | 3 |
| Capex | 0 | 0 | (0) | 0 | 0 |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Profit before tax | 0 | 0 | (0) | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | (0) | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.10 | 0.10 | (0.10) | 0.02 | 0.02 | 0.00 | 0.00 | 0.03 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| CRISIL LTD | 33,999 | 38.5 | 10.39 | — | 13.7 | 16.1 | — | 30.6 |
| ONEMI TECHNOLOGY SOL LTD | 5,509 | 19.5 | 4.10 | 9.4 | 21.0 | 18.8 | — | 32.0 |
| GYFTR LIMITED | 1,234 | — | 2.54 | 37.9 | 4.5 | 5.3 | 32.8 | 4.3 |
| CENTRUM CAPITAL LIMITED | 969 | — | 0.74 | 9.7 | (21.4) | (2.5) | 49.7 | 29.7 |
| PRIME SECURITIES LIMITED | 968 | 172.9 | 3.78 | — | 5.1 | — | 25.7 | 19.0 |
| WEALTH FRST PORT. MG. LTD | 881 | 26.7 | 5.18 | 16.9 | 22.5 | 30.3 | — | 97.5 |
| REGENCY FINCORP LIMITED | 571 | 52.3 | 3.56 | — | 8.4 | — | — | 84.3 |
| STELLANT SECURITIES (INDIA) LT | 529 | — | 1687.57 | — | 18.2 | 18.2 | — | 56.7 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 30.0 | 19.0 | 48 of 76 | 37% |
| P/B | 0.1 | 1.0 | 10 of 105 | 90% |
| ROCE | 0.7 | 1.8 | 52 of 83 | 38% |
| ROE | 0.5 | 1.3 | 67 of 111 | 40% |
| Debt / Equity | 0.0 | 0.0 | 1 of 77 | 55% |
| EBITDA margin | 41.2 | 25.6 | 34 of 91 | 63% |
| Revenue growth | (44.3) | (4.1) | 64 of 85 | 25% |
| Profit growth | 15.6 | (0.2) | 51 of 109 | 54% |
| Market cap | 5 | 26 | 104 of 113 | 8% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 12 Oct 2026 · Quarterly compliance filing on share dematerialization for Q2 FY26 | compliance | minimal | — | — |
| 5 Oct 2026 · BSE seeks clarification on significant price movement | regulatory legal | high | — | — |
| 29 Sept 2026 · 47th AGM voting results: Both resolutions passed with 99.98 percent approval | compliance | minimal | — | — |
| 28 Sept 2026 · Trading window closed from Oct 1, 2026 for Q2 FY27 results | compliance | minimal | — | — |
| 28 Sept 2026 · 47th AGM concluded; financials adopted, Director reappointed by rotation | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Notice of AGM published in newspapers | compliance | minimal | — | — |
| 4 Sept 2026 · Symbiox Investment submits FY26 Annual Report; revenue drops 42 percent | results | medium | — | — |
| 4 Sept 2026 · Notice of 47th AGM and Annual Report web-link shared with shareholders | compliance | minimal | — | — |
| 4 Sept 2026 · Book Closure and Record Date for 47th AGM | board shareholder meetings | low | — | — |
| 4 Sept 2026 · 47th AGM Notice - 28 September 2026 via Video Conferencing | board shareholder meetings | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.